The prolongation of progression-free survival (PFS) in patients with advanced ovarian cancer by anti-angiogenic therapy has been shown in several clinical trials. However, although an anti-VEGF antibody (bevacizumab) is the only option currently available, its efficacy is limited and it is not cost-effective for use in all patients. Therefore, the development of a novel anti-angiogenic drug, especially composed of small molecule compounds, could be a powerful armament for ovarian cancer treatment. Since NF-κB signaling has the potential to regulate VEGF expression, we determined to identify whether VEGF expression is associated with NF-κB activation and to investigate the possibility of a novel IKKβ inhibitor, IMD-0354 (IMMD Inc. Tokyo, Japan), as an antiangiogenic drug.
IKKβ regulates VEGF expression and is a potential therapeutic target for ovarian cancer as an anti-angiogenic treatment
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Abstract
The prolongation of progression-free survival (PFS) in patients with advanced ovarian cancer by anti-angiogenic therapy has been shown in several clinical trials. However, although an anti-VEGF antibody (bevacizumab) is the only option currently available, its efficacy is limited and it is not cost-effective for use in all patients. Therefore, the development of a novel anti-angiogenic drug, especially composed of small molecule compounds, could be a powerful armament for ovarian cancer treatment. Since NF-κB signaling has the potential to regulate VEGF expression, we determined to identify whether VEGF expression is associated with NF-κB activation and to investigate the possibility of a novel IKKβ inhibitor, IMD-0354 (IMMD Inc. Tokyo, Japan), as an antiangiogenic drug.
Tissue microarrays from 94 ovarian cancer tissues were constructed and immunohistochemical analyses performed. We revealed that IKK phosphorylation is an independent prognostic factor (PFS; 26.1 vs. 49.8 months, P=0.011), and is positively correlated with high VEGF expression. In in vitro analyses, IMD-0354 robustly inhibited adhesive and invasive activities of ovarian cancer cells without impairing cell viabilities.
IMD-0354 significantly suppressed VEGF production from cancer cells, which led to the inhibition of angiogenesis. In a xenograft model, the treatment of IMD-0354 significantly
Introduction
The prognoses of ovarian cancer patients have remained much the same since the late 1990s, and for this reason, a large number of novel molecular targeted agents and innovative therapeutic associations of chemotherapy have been attempted and remain under investigation (1, 2) . Among the new drugs studied for ovarian cancer, bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has shown promising activities in combination with standard chemotherapy in several Phase III trials, such as the ICON7 and GOG218 studies (3, 4) .
Angiogenesis has been shown to be an important contributor to ovarian carcinogenesis and progression. Among various angiogenic factors, VEGF, the most endothelial cell-specific angiogenic factor characterized to date, induces endothelial cell proliferation, promotes cell migration and inhibits apoptosis. VEGF is firmly believed to be a key regulator of physiological and pathological angiogenesis (5) . Thus, it is likely that bevacizumab would be a powerful tool for ovarian cancer treatment. It has shown revolutionary efficacies not only as a first-line therapy combined with paclitaxel plus carboplatin but also as a treatment for relapsed cases. However, several concerns remain unresolved. In Phase III trials (ICON7 and GOG218), although maintenance treatment with bevacizumab extended the length of progression-free survival (PFS), this advantage stopped 10 months after the cessation of treatment and only ICON7 showed a trend towards improved overall survival (OS) in a subgroup of patients with high-risk disease (3, 4) . In platinum-sensitive relapse, although bevacizumab has also been shown to improve PFS (OCEANS) (6) , no overall survival benefit was found. In platinum-resistant relapse, a recent Phase III trial (AURELIA) reported an increase in response rate and a doubling of PFS (6.7 vs. 3.4 months) in those who received single agent chemotherapy plus bevacizumab compared with chemotherapy alone, while the effect on OS has not been reported (2, 7) . These clinical data indicate that, in order to improve OS, long-term continuous anti-angiogenic maintenance therapy would be indispensable until patients show progressive disease.
However, the pharmacoeconomic issue is obviously a major obstacle for clinical longterm use of bevacizumab in every patient. Hensley costs $78.3 million for 3.8 progression-free months for 600 women (8). Hence, we believe that it would be meaningful to find better compounds that specifically inhibit angiogenesis with safety profiles, given that anti-angiogenic therapy is to be used in combination with cytotoxic chemotherapies. Indeed, anti-angiogenic molecules have been developed and many clinical trials are underway (9).
Nuclear factor-kappa B (NF-κB) is an inducible transcription factor that regulates a wide variety of gene expressions. Constitutive NF-κB signaling has been identified in tumors of epithelial origin, including breast, colon, lung, and ovarian carcinomas (10), and numerous in vitro and in vivo studies have suggested that NF-κB plays an important role in cancer progression including angiogenesis (11) . Although various studies have suggested that NF-κB signaling correlates with angiogenesis, the importance of NF-κB in terms of VEGF expression remains controversial (12, 13, 14) .
In addition, the prognostic value of high NF-κB activity on ovarian carcinomas is also controversial. Kleinberg et al. reported that the nuclear localization of NF-κB/RelA (p65) is frequently expressed in advanced-stage serous ovarian carcinomas, and is associated with poor PFS (15), while Annunziata et al. wrote that high expression of cytoplasmic NF-κB1 (p50) was associated with poor survival in advanced-stage ovarian cancer patients (16 accumulation of p65 in epithelial ovarian carcinomas is significantly associated with a good response to chemotherapy and can predict longer OS of patients (17) . For these reasons, we were encouraged to analyze whether NF-κB signaling regulates VEGF expression in ovarian cancer tissues as well as whether targeting this signaling can be an alternative option for the inhibition of VEGF expression, leading to a new antiangiogenic therapy.
The NF-κB/Rel family includes NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB, and c-Rel. They can all form homo-and heterodimers, with the most abundant form being p50/p65 (18) . These dimers are present in the cytosol in an inactive form, complexed with proteins of the IκB family. Upon stimulation, phosphorylation of IκB by IκB kinase (IKK) leads to degradation of IκB and renders NF-κB free to translocate into the nucleus. The nuclear NF-κB binds to promoters and enhancers, leading to gene transcription (11) . Two IκB kinases, IKKα and IKKβ, have been well described. It is known that they have nonequivalent functions and that activation of IKK-β, rather than IKK-α, participates in the primary pathway by which proinflammatory stimuli activate NF-κB (18) . Given that the indispensable roles played by NF-κB in many biological processes raise the concern that a complete shutdown of this pathway would have significant detrimental effects on normal cellular function, drugs that selectively target only IKK-β activity could be of greater therapeutic value (19) . IMD-0354 is a newly synthesized low-molecular-weight compound that selectively inhibits IKKβ in the IKK complex. IMD-1041 is a prodrug of IMD-0354 for oral administration and on its way to clinical application at present. A Phase 1 study was completed and up to 12 weeks of IMD-1041 administration proved to be sufficiently safe with very few adverse events ranked as mild (20) . Therefore, we determined to elucidate the effect of this drug on ovarian cancer cells, focusing especially on VEGF expression.
With these goals in mind, we first constructed tissue microarrays (TMAs) from ovarian cancer samples and immunostained them with phosphorylated-IKK and VEGF antibody. We revealed that IKK phosphorylation is an independent prognostic factor and that its expression was positively correlated with high VEGF expression, suggesting that NF-κB activation regulates VEGF expression in ovarian cancer tissues.
Further, we assessed the potential of a small molecular-weight IKK inhibitor, IMD-0354, as a novel therapeutic option for anti-angiogenic treatment against ovarian cancer. days, ES-2; 3 days), the mice were intraperitonally administered either 0.5 mL of 0.5% carboxymethylcellulose sodium salt (CMC-Na; Wako, Osaka, Japan) or IMD-0354 (30 mg/kg) every day for a total of 6 weeks to the SKOV3ip1 inoculated mice or 11 days to the ES-2 inoculated mice and finally sacrificed. The number of metastases and the volume of ascites in each mouse was counted, carefully dissected and the removed tumors weighed. Tumor tissues were immediately fixed and embedded in paraffin. The slides were prepared and incubated with p-IKKα/β antibody at 1:150, human VEGF antibody at 1:40, mouse CD-31 antibody, Ki-67 antibody, and cleaved caspase-3 antibody at 1:300 for 1 hour at room temperature. After washing with TBST, they were stained using N-Histofine Simple Stain MAX PO(R) (Nichirei Biosciences, Tokyo, Japan) and then counterstained with Carrazzi's hematoxylin.
Statistical analysis. Statcel version 3 (OMS-Publishing Inc., Saitama, Japan) and JMP version 10.0.2 (SAS Institute Japan Ltd., Tokyo, Japan) were used for statistical analyses. Data were expressed as means ± SEM. Differences were analyzed using the Mann-Whitney U test. Survival estimates were computed using the Kaplan-Meier method, and comparisons between groups were analyzed using the log-rank test.
Multivariable analysis was performed using a Cox proportional-hazards regression model. Differences were considered statistically significant at P < 0.05. The correlation of IKK phosphorylation and VEGF expression was examined with the χ 2 test, revealing that these expressions were significantly positively correlated (Fig. 2D, Figure 3A) , a specific IKK-β inhibitor selectively blocking IκBα phosphorylation (IC 50 ; ≤ 250 nM) (24) was used for the experiments. Although IMD-0354 at up to 1 M did not affect the viabilities of SKOV3ip1 or RMUG-S ovarian cancer cells (Fig. 3B) , it inhibited the constitutive phosphorylation of IKK (Fig. 3C) . In order to determine the effect of IMD-0354 on NF-κB activation, the localization of NF-κB p65 was examined by immunofluorescence analyses. SKOV3ip1 cells were immunostained with an anti-p65 antibody and cell nuclei were identified by co-staining with DAPI. NF-κB p65 was dominantly located in the cytoplasm in the control and upon TNF-αstimulation, p65 drastically translocated into nuclei. The pretreatment of 0.1 M IMD-0354 almost inhibited its nuclear translocation (Fig. 3D) . 
P=0.037).

Constitutive activation of NF-κB in ovarian cancer cells was inhibited by IMD-
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, respectively) in a dose dependent manner (Fig. 4A) . In order to analyze how IMD-0354 inhibited cell adhesion, the expressions of various integrins were examined by Western blot (Fig. 4C) . β1-integrin expression was inhibited by IMD-0354 treatment in each ovarian cancer cell line tested (SKOV3ip1, RMUG-S, and CaOV3), while the expressions of the other integrins tested (α1, α2, α5 and β3-integrin) were not altered.
Cell invasion follows adhesion. In vitro invasion assay revealed that IMD-0354 significantly impaired the invasion of cancer cells (0.3 M: SKOV3ipi, 27%; RMUG-S, 33%, respectively) (Fig. 4D) . The expression of matrix metalloproteinase 2 (MMP-2), known as an important molecule in ovarian cancer invasion, was inhibited by the treatment with IMD-0354 (Fig. 4E) .
IMD-0354 inhibits VEGF production from ovarian cancer cells, leading to the inhibition of angiogenesis. Next, we examined the effect of IMD-0354 on VEGF production from cancer cells. Luciferase assay revealed that VEGF-A transcriptional activity was significantly inhibited by IMD-0354 in a dose dependent manner (Fig. 5A) .
Several possible NF-κB-like binding sites within the VEGF 5'-promoter region were previously reported (12) and pGL4-phVEGFA plasmid has two possible binding sites (4332-4341, 4992-4931) (Fig. 5B) . Thus, 5′-deletion mutant (mut pGL4-phVEGFA) was made by deleting fragments containing these sites and a luciferase assay was (Fig. 5C) . Luciferase activity was drastically abolished and IMD-0354 did not show any inhibitory effects, indicating that NF-κB directly regulates VEGF promoter activity. Accordingly, IMD-0354 treatment of SKOV3ip1 cells resulted in a decrease in the levels of VEGF-A protein from 1.61 ng/ml to 0.97 ng/ml as evidenced by quantitative ELISA (Fig. 5D) . To clarify the anti-angiogenic effect of IMD-0354 in vitro, the migratory activity of HUVECs was examined by a wound healing assay.
Representative images are shown in Fig. 5E . VEGF-A 5 ng/ml was used as a positive control. The direct treatment of IMD-0354 to HUVECs did not affect the migration.
While SKOV3ip1 culture media induced HUVECs migration and almost restored the scratched wound after 48 h of incubation, the pre-treatment of IMD-0354 to SKOV3ip1 cells inhibited HUVECs migration (Fig. 5F) . The co-treatment of VEGF-A almost abolished the inhibitory effect of IMD-0354, indicating that IMD-0354 inhibited the migratory activity of HUVECs by inhibiting VEGF production from SKOV3ip1 cells. omentum, the surface of the liver and the small bowel mesentery. As preliminary experiments, dose finding study (7.5 mg, 15 mg or 30 mg/kg) was performed and 30 mg/kg showed the maximum effect without apparent adverse events on mice (Supplemental Fig. 1 ). Six weeks after treatment, both the tumor weight and the number of peritoneal implants were significantly inhibited in mice treated with IMD-0354 compared with controls (tumor weight: IMD-0354; 176.2 ± 136.9 vs. control; 518.6 ± 338.4 mg, number of peritoneal implants: 1.9 ± 2.7 vs. 26.1 ± 17.2, respectively, P < 0.001) (Fig. 6A and 6B) . Similarly, in another ovarian cancer xenograft model with ES-2, IMD-0354 significantly exerted anti-tumor effects on tumor weight, number of peritoneal metastases, and ascites formation compared with the control (tumor weight: IMD-0354; 227.6 ± 109.8 vs. control; 576.5 ± 180.6 mg, P < 0.001, number of peritoneal implants: 15.4 ± 6.7 vs. 31.8 ± 10.1, P < 0.001, ascites: 1.06 ± 0.72 vs. 2.84 ± 1.28 g, P < 0.01, respectively,) (Fig. 6C, 6D, and 6E) . In order to analyze how IMD-0354 worked in vivo, immunohistochemical analyses from inoculated tumors were performed (Fig. 6F) . Not only the phosphorylation of IKK but the expression of human ± 36.1 /× 200 field, respectively, P < 0.01) (Fig. 6G) . In contrast, the staining of peritoneal tumors with the proliferation marker Ki-67 and the apoptotic marker cleaved caspase-3 did not show significant difference between IMD-0354 treated mice and controls ( Fig. 6H and 6I) , suggesting that IMD-0354 inhibited ovarian cancer progression by inhibiting angiogenesis through the suppression of VEGF production from cancer cells.
IMD-0354 inhibits peritoneal metastasis in an ovarian
Discussion
In this study, we revealed that, in more than 80 % of ovarian cancer cases, IKK is phosphorylated and its phosphorylation is an independent prognosis factor for patients and positively correlates with high VEGF expression. Furthermore, using a new IKKβ inhibitor, IMD-0354, we showed that this drug not only suppressed the adhesion and invasion of ovarian cancer cells but also transcriptionally inhibited VEGF production from cancer cells, which led to attenuation of the migration of endothelial cells induced by cancer cells. In a xenograft model, the treatment with IMD-0354 significantly inhibited peritoneal dissemination with a marked reduction of blood vessel formation.
Thus, we suggest that an IKKβ inhibitor such as IMD-0354 can be considered to be an anti-angiogenic agent and a potential treatment for ovarian cancer, given that VEGF is 
induced apoptosis of cancer cells. Indeed, in our experience, 10 M of IMD-0354 comprehensively induced apoptosis of ovarian cancer cells tested by G0/G1-phase cell cycle arrest (data not shown). However, given that the IC 50 value for IKKβ of IMD-0354 is ≤ 250 nM, these apoptotic effects appear to be caused by a non-specific toxicity of the drug. Further elucidation would be required to identify how IMD-0354 works on cancer cells.
In immunohistochemical analyses, 81 of 94 (86%) ovarian cancer samples showed positive phosphorylated IKK expression. This is similar to previous findings (15, 16, 17) . Although some in vitro studies using ovarian cancer cell lines suggested that NF-κB regulates VEGF expression (37), to our knowledge, none has reported the direct correlation of NF-κB activation and VEGF expression in clinical samples. In the present study, we reported that ovarian cancer tissues with posive p-IKK staining significantly expressed high levels of VEGF, proposing a clear rationale that targeting IKK phosphorylation can be considered an anti-angiogenic therapy for ovarian cancer treatment.
In conclusion, IKK phosphorylation is an independent prognostic factor and is associated with VEGF expression in cancer cancer tissues. IMD-0354 not only inhibited ovarian cancer invasion but suppressed VEGF production from cancer cells in and values are means ± SEM, n.s.; not significant, *; P < 0.05, **; P < 0.01, ***; P < 0.001. expressed as mean ± SEM, n=5, each. n.s.; not significant, **; P < 0.01, ***; P < 0.01. 
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